Moderna, Inc. (MRNA) Advances Flu, RSV, and Cancer mRNA Therapies Beyond COVID

In this article, we will be taking a look at the Top 10 AI-Powered Biotech Stocks to Buy Now. Moderna, Inc. is placed among them.

Moderna, Inc. (NASDAQ:MRNA), a Cambridge-based biotechnology leader, specializes in mRNA therapeutics and vaccines, including its flagship COVID-19 vaccine. Beyond the pandemic, the company is expanding its pipeline with vaccines for influenza, RSV, CMV, Zika, and combination vaccines targeting multiple respiratory pathogens, alongside mRNA therapeutics for oncology, rare diseases, and cardiovascular conditions. MRNA operates globally with manufacturing in the U.S. and Europe, leveraging strategic alliances and technology transfers to scale its operations.

In September 2025, Moderna, Inc. (NASDAQ:MRNA) faced market headwinds as its stock fell nearly 7%, triggered by reports linking COVID-19 vaccines to about 25 child deaths, a claim lacking scientific consensus but fueling investor concerns and regulatory scrutiny. Policy shifts, including Florida’s removal of vaccine mandates, further cloud near-term demand forecasts.

Despite these challenges, the firm emphasizes transparency and scientific rigor, citing extensive real-world data with over a billion doses administered worldwide. This ongoing focus on safety underpins public trust and regulatory engagement.

Innovation remains central to Moderna, Inc. (NASDAQ:MRNA)’s strategy, with the company broadening mRNA applications beyond COVID-19. AI and machine learning are increasingly integrated into MRNA’s R&D pipeline to accelerate mRNA design, optimize vaccine formulations, and predict immune responses. This combination of scientific rigor and technological edge reinforces MRNA’s standing among the best biotech stocks adapting to future healthcare needs.

While we acknowledge the potential of MRNA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.